| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Apr―05 |
Alpha-1 adrenergic antagonists and the risk of hospitalization or death in non-hospitalized patients with COVID-19: A population-based study |
Tony Antoniou, Daniel McCormack, Mina Tadrous, Tara Gomes |
| 2 |
[GO] |
2024―Feb―12 |
Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID-19 |
Liyan Zeng, Rui Chen, Xuhua Jiang, Feng Li, Zhaoqin Zhu, Zheng Jiao, Yun Ling, Lijun Zhang |
| 3 |
[GO] |
2023―Nov―21 |
An exploratory study of drug concentration and inhibitory effect of cetylpyridinium chloride buccal tablets on SARS-CoV-2 infection among 10 Chinese subjects |
Yanting Li, Zhenwei Xie, Liming Chen, Xiangxing Liu, Shuang Li, Shichun Ye, Hongyan Tang, Chongyou Lee, Qun Gu, Fang Men, Jiaojiao Zhang, Dingyuan Hu, Yuanli Jiang, Xiaochun Wang, Qian Wang, Yufei Feng, Suping Niu, Yan Liu, Yi Fang |
| 4 |
[GO] |
2023―Nov―11 |
Alterations in the gene expression of SARS-COV-2 entry receptors and enzymes in lungs and hearts of controlled and uncontrolled diabetic mice |
Ohood Alkhawaldeh, Yazun Jarrar, Munir Gharaibeh, Sara Abudahab, Dina Abulebdah, Bashir Jarrar |
| 5 |
[GO] |
2023―Jul―20 |
Vestibular disorders following BNT162b2 mRNA COVID-19 vaccination: A retrospective case series |
Helmi Ammar, Christine Le Beller, Didier Bouccara, David Malinvaud, Romain Jouffroy, Agnès Lillo-Le Louet |
| 6 |
[GO] |
2023―May―11 |
Treatment implications of augmented renal clearance in a critically ill COVID-19 patient: a case report |
Susan Deenen, Laura F. C. Fransen, Tessa C. C. Jaspers, Jessica D. Workum |
| 7 |
[GO] |
2023―Mar―18 |
Viral target- and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: molnupiravir, nirmatrelvir and remdesivir |
Daisy Yan, Bingfang Yan |
| 8 |
[GO] |
2022―May―14 |
Melatonin as a complementary and prophylactic agent against COVID-19 in high-risk populations: A narrative review of recent findings from clinical and preclinical studies |
Abdolkarim Hosseini, Taleb Badri, Hadi Esmaeili Gouvarchin Ghaleh, Kazem Hassanpour, Gholam Hossein Alishiri, Mostafa Akbariqomi, Gholamreza Farnoosh |
| 9 |
[GO] |
2022―May―09 |
Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on Eudravigilance data |
Domenico Motola, Giulia Bonaldo, Nicola Montanaro |
| 10 |
[GO] |
2022―May―03 |
NVX-Cov2373 Novavax Covid-19 vaccine: a further analysis of its efficacy using multiple modes of expression |
Jean-Louis Montastruc, Pierre Biron, Agnès Sommet |
| 11 |
[GO] |
2021―Jul―16 |
In vitro
inhibition and molecular docking of a new ciprofloxacin chalcone against SARS-CoV-2 main protease |
Rania Alaaeldin, Muhamad Mustafa, Gamal El-Din A. Abuo-Rahma, Moustafa Fathy |
| 12 |
[GO] |
2021―Jul―12 |
Efficacy of Covid-19 vaccines: several modes of expression should be presented in scientific publications |
Jean-Louis Montastruc, Pierre Biron, Agnès Sommet |
| 13 |
[GO] |
2021―May―11 |
COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database |
Amandine Dernoncourt, Jean Schmidt, Pierre Duhaut, Sophie Liabeuf, Valérie Gras-Champel, Kamel Masmoudi, Youssef Bennis, Benjamin Batteux |
| 14 |
[GO] |
2021―Apr―20 |
Chronic use of Renin-Angiotensin-Aldosterone-System blockers and mortality in COVID-19: a multicenter prospective cohort and literature review |
Nathalie Gault, Marina Esposito-Farese, Matthieu Revest, Jocelyn Inamo, André Cabie, Élisabeth Polard, Jean-Sébastien Hulot, Jade Ghosn, Catherine Chirouze, Laurène Deconinck, Jean-Luc Diehl, Julien Poissy, Olivier Epaulard, Benjamin Lefèvre, Lionel Piroth, Etienne de Montmollin, Eric Oziol, Manuel Etienne, Cédric Laouenan, Patrick Rossignol, Dominique Costagliola, Emmanuelle Vidal-Petiot |
| 15 |
[GO] |
2021―Jan―15 |
A systematic review of experimental evidence for antiviral effects of ivermectin and an in-silico analysis of ivermectin's possible mode of action against SARS-CoV-2 |
Robert T. Kinobe, Leigh Owens |
| 16 |
[GO] |
2020―Dec―09 |
Outcome of patients hospitalized for Covid-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: Results of the ACECoV study |
Joachim Alexandre, Jean-Luc Cracowski |
| 17 |
[GO] |
2020―Oct―28 |
Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study |
Margaux Lafaurie, Guillaume Martin-Blondel, Pierre Delobel, Sandrine Charpentier, Agnès Sommet, Guillaume Moulis |
| 18 |
[GO] |
2020―Jul―13 |
Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin |
Hakan Parlakpinar, Seyhan Polat, Hacı Ahmet Acet |
| 19 |
[GO] |
2020―Jul―02 |
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments |
Nicolas Venisse |
| 20 |
[GO] |
2020―Jun―30 |
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments |
Florian Lemaitre, Caroline Solas, Matthieu Grégoire, Laurence Lagarce, Laure Elens, Elisabeth Polard, Béatrice Saint-Salvi, Agnès Sommet, Michel Tod, Chantal Barin-Le Guellec |
| 21 |
[GO] |
2020―May―12 |
Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic |
Louis Larrouquere, Manon Gabin, Emmanuelle Poingt, Amelle Mouffak, Alex Hlavaty, Marion Lepelley, Charles Khouri, Alexandre Bellier, Joachim Alexandre, Pierrick Bedouch, Laurent Bertoletti, Regis Bordet, Béatrice Bouhanick, Annie-Pierre Jonville-Bera, Silvy Laporte, Claire Le Jeunne, Louis Letinier, Joëlle Micallef, Florian Naudet, Matthieu Roustit, Mathieu Molimard, Vincent Richard, Jean-Luc Cracowski |
|
